Actively Recruiting
Early Feasibility Study to Evaluate Safety and Performance of Innoventric Trillium Stent Graft for Severe Tricuspid Regurgitation Treatment
Led by Innoventric LTD · Updated on 2026-11-04
25
Participants Needed
10
Research Sites
258 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and performance of the Innoventric Trillium Stent Graft in treating patients with severe or greater tricuspid regurgitation TR. This early feasibility study involves up to 15 patients across investigational sites in the US and Germany. The study focuses on patients who have significant TR and are not suitable for or have refused standard surgical or interventional therapies. Participants will undergo a transcatheter cross-caval tricuspid valve replacement using the Innoventric Trillium Stent Graft. This device-based treatment is delivered during a single procedure. Following the procedure, patients will be monitored at discharge and at multiple follow-up points including 1 month, 3 months, 6 months, and yearly up to 5 years to assess the devices safety and technical performance. During the study, patients will have assessments at baseline, during the procedure, and at scheduled follow-ups. These evaluations include monitoring for major adverse events shortly after the procedure and over several years, as well as checking the devices efficacy. The total participation duration can extend up to 5 years, with visits designed to track safety, performance, and patient outcomes over time.
CONDITIONS
Brief Title
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
Research Team
C
Chen Lereya
A
Amir Danino
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here